SDRI 2017 conference blogs

In the following series of blogs, brought to MedChemNet users by ID Hub, Ruth Neale (Community for Open Antimicrobial Drug Discovery, Brisbane, Australia) provides daily summaries of the events that unfolded at SDRI 2017, held in Brisbane, Australia, 3–5 April 2017.

0
0
Upvote 0 Comment

SDRI 2017 is a multi-disciplinary scientific conference for the Asia Pacific region focused on Solutions for Drug-Resistant Infections. This inaugural conference theme is New Drugs for Drug-Resistant Infections. The conference took place at the Brisbane Convention and Exhibition Centre in Australia from 3 - 5 April, 2017.

The program provided a fantastic forum for researchers and industry representatives working in the space of microbiology, virology, parasitology, genomics, pharmacology and medicinal chemistry, to network and discuss new ways to solve the global challenge of drug-resistant infections.


SDRI conference blog – day one

The idea of ‘SDRI 2017’ was conceived in Brisbane by Matthew Cooper’s antibiotic research group and organized by the Community for Antimicrobial Drug Discovery (CO-ADD) (both University of Queensland (UQ), Australia). The theme of this inaugural conference is New Drugs for Drug-Resistant Infections. Over the next 3 days we welcome a range of distinguished invited speakers who are world leading experts in research, industry, funding and policy in the field of drug-resistant infections.

To the read the full article, click here.

SDRI conference blog – day two

The day began with Ramanan Laxminarayan from the Center for Disease Dynamics, Economics & Policy (CDDEP), Public Health Foundation Indian (PHFI) and Princeton! His long standing experience in advisory work at an international level for the WHO, World Bank and his amazing and unique set of skills – mixing economics and epidemiology – made an inspirational plenary talk to kick off day two.

To read the full article, click here.

SDRI conference blog – day three

The day began with antibiotic drug discovery expert John Rex. Rex, a physician and drug developer, has an impressive background with ~30 years of development and policy experience focused on antimicrobial agents. Currently Chief Strategy Officer for CARB-X and working for the Wellcome Trust (London, UK), Rex spoke about the successes and failures of those navigating the antibiotic drug discovery pipeline.

To read the full article, click here.


Go to the profile of Infectious Diseases Hub

Infectious Diseases Hub

The online home of infectious disease information and research, Future Science Group

Your source for up-to-date, essential research and information on all aspects of virology and microbiology, from bench to bedside.
1 Contributions
2 Followers
0 Following

0 Comments